Nutritional supplements that contain curcumin -- a natural anti-inflammatory compound -- may protect the eyes from the ...

The therapy, called photobiomodulation or “red light” therapy, can reduce the risk of vision loss and slow progression of the ...

Light therapy could be a useful treatment for the most common form of age-related macular degeneration ... drugs available for people with "wet" AMD, in which leaking blood vessels damage the ...

There are various factors that may potentially increase the risk of developing AMD, such as advancing age (over 50); having a ...

Pharmaceuticals announced that the first patient has been dosed in the Phase 3 LUGANO clinical trial of DURAVYU, formerly ...

Dr Arshad Khanani anticipates presentations offering new strategies to tackle challenges such as macular atrophy and fibrosis, and optimizing dosing intervals in wet AMD.

Dr. Shiri Shulman from Assuta discusses the importance of continuity in treatment during wartime and innovative therapies ...

Age-related macular ... good treatment outcome with few treatments needed. Large controlled studies are needed to achieve the best combination therapy for CNV. Age-related macular degeneration ...

While adverse events (AEs) were reported for 97% of trial participants, such cases were predominantly mild to moderate.

REGENXBIO Inc. (Nasdaq: RGNX) today announced positive data from the Phase II fellow eye sub-study evaluating the subretinal delivery of ABBV-RGX-314 in patients with bilateral wet age-related macular ...

Alkeus Pharmaceuticals’ study results from Gildeuretinol shows significant trend in slowing geographic atrophy: Cambridge, Massachusetts Friday, October 25, 2024, 10:00 Hrs [IST ...